<span item_type="fundamental" item_id="0fccc31d7b7db280718c16b404ae90b6" counter_id="ST/US/TLSIW" env="prod"></span><span item_type="announcement" item_id="548716675809611521" env="prod"></span><p>Revenue: As of FY2025 Q2, the actual value is USD 11.21 M.</p><p>EPS: As of FY2025 Q2, the actual value is USD -0.27.</p><p>EBIT: As of FY2025 Q2, the actual value is USD -6.837 M.</p><p></p><h3>Segment Revenue</h3><ul><li>TriSalus Life Sciences reported $11.2 million in revenue for the second quarter of 2025, marking a 52% increase year-over-year and a 22% growth quarter-over-quarter, driven by increased selling resources and market share expansion.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1826667/000182666725000115/q22025earningsrelease.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>Gross margins were 84% in the second quarter, down from 88% in the same period of 2024, due to lower manufacturing efficiency associated with newly launched products.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1826667/000182666725000115/q22025earningsrelease.htm"></span></li><li>Research and Development expenses decreased to $3.9 million from $4.7 million in the same quarter of the prior year, primarily due to reduced clinical trial costs for Nelitolimod.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1826667/000182666725000115/q22025earningsrelease.htm"></span></li><li>Sales and Marketing expenses increased to $7.2 million from $6.0 million, reflecting continued investment in commercial expansion.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1826667/000182666725000115/q22025earningsrelease.htm"></span></li><li>General &amp; Administrative expenses rose to $5.7 million from $4.0 million, mainly due to increased professional services costs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1826667/000182666725000115/q22025earningsrelease.htm"></span></li><li>Operating losses were reduced to $7.3 million from $8.2 million in 2024, attributed to decreased R&amp;D expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1826667/000182666725000115/q22025earningsrelease.htm"></span></li><li>Net loss attributable to common stockholders was $9.0 million, compared to $5.1 million in 2024, primarily due to non-cash adjustments to the fair value of contingent earnout liability.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1826667/000182666725000115/q22025earningsrelease.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>As of June 30, 2025, cash and cash equivalents totaled $26.5 million, providing sufficient runway to reach positive adjusted EBITDA in the first half of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1826667/000182666725000115/q22025earningsrelease.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>Adjusted EBITDA losses were $5.3 million, compared to losses of $6.7 million for the same period in 2024, due to increased sales, reduced R&amp;D expenses, and increased stock compensation.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1826667/000182666725000115/q22025earningsrelease.htm"></span></li></ul><h3>Outlook / Guidance</h3><ul><li>TriSalus Life Sciences reaffirmed its full-year revenue growth guidance of 50%, driven by increasing market penetration within liver-directed therapies and continued commercial momentum.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1826667/000182666725000115/q22025earningsrelease.htm"></span></li></ul>

TriSalus Life Sciences - CW | 8-K: FY2025 Q2 Revenue: USD 11.21 M